Fulvestrant 250mg Injection
Rx RequiredSalt Composition: Fulvestrant
Expiry Date: 01/2028
Buy at $56.47
Inclusive of all taxes
1 Injection
About The Product
Breast Cancer
Fulvestrant 250mg Injection is an anticancer medicine that is prescribed to treat breast cancer in postmenopausal women. It is a selective estrogen receptor degrader medicine as it works by blocking the activity of the estrogen hormone and controlling the growth of cancer cells. Fulvestrant 250mg Injection can be used as a single treatment or combined with specific chemotherapy drugs to manage hormone receptor-positive, advanced breast cancer or metastatic breast cancer in adult patients whose condition worsens during or after certain other treatments.
Side Effects
- Fulvestrant 250mg Injection shows some adverse impact on the body during the treatment.
- Most of the effects are manageable and resolve on their own.
- Some common side effects include: Headache Fever Vomiting Diarrhea Nausea Allergic reaction Urine infection Chills Weight loss Tiredness Drowsiness Itching Skin rash Seek medical advice if the symptoms continue or if you have concerns about them
How To Use
- Fulvestrant 250mg Injection shows some adverse impact on the body during the treatment.
- Most of the effects are manageable and resolve on their own.
- Some common side effects include: Headache Fever Vomiting Diarrhea Nausea Allergic reaction Urine infection Chills Weight loss Tiredness Drowsiness Itching Skin rash Seek medical advice if the symptoms continue or if you have concerns about them
Safety Advice
Missed Doses
- It is advisable not to miss any dose.
- In case you miss a dose of Fulvestrant 250 mg injection consult your doctor soon.
- Missing the dose will impact the overall health of the patients.
- So, it is always advisable to follow the prescription of the doctor strictly.
FAQs
Fulvestrant injection is an anti-cancer medication, prescribed for the treatment of Breast Cancer in postmenopausal women.
Reference
1. Howell, A., & Sapunar, F. (2011). Fulvestrant revisited: efficacy and safety of the 500-mg dose. Clinical breast cancer, 11(4), 204-210.
2. Bross, P. F., Cohen, M. H., Williams, G. A., & Pazdur, R. (2002). FDA drug approval summaries: fulvestrant. The oncologist, 7(6), 477-480.
3. Leo, A. D., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., ... & Martin, M. (2014). Final overall survival: fulvestrant 500mg vs 250mg in the randomized CONFIRM trial. Journal of the National Cancer Institute, 106(1), djt337.
4.https://www.ncbi.nlm.nih.gov/books/NBK560854/
5.https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021344s015lbl.pdf
.jpeg%3FupdatedAt%3D1763121181831&w=128&q=75 "Venika Choudhary")
.png%3FupdatedAt%3D1763121181806&w=128&q=75 "Dr. Aditya Sarin")
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
